Odds ratios for disease manifestation in adults in Sweden among serotypes included or not included in the conjugated vaccines (7-, 10- or 13-valent vaccines)
| Serotype group | Patients n | Mean age years | Pneumonia | Meningitis | Septicaemia | Underlying disease | Mortality | |||||
| n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | |||
| 7-valent vaccine | 988 | 64 | 806 (82) | 0.52 (0.36–0.76) | 64 (6) | 1.82 (0.99–3.34) | 100 (10) | 1.98 (1.20–3.29) | 651 (66) | 3.25 (2.52–4.18) | 106 (11) | 3.43 (1.86–6.30) |
| 1, 5, 7F (10-valent) | 354 | 53 | 316 (90) | 1 (Ref) | 13 (4) | 1 (Ref) | 19 (5) | 1 (Ref) | 132 (37) | 1 (Ref) | 12 (3) | 1 (Ref) |
| 7-valent vaccine | 988 | 64 | 806 (82) | 0.87 (0.61–1.25) | 64 (6) | 0.87 (0.52–1.46) | 100 (10) | 1.27 (0.79–2.06) | 651 (66) | 0.69 (0.51–0.93) | 106 (11) | 0.59 (0.40–0.85) |
| 3, 6A, 19A (13-valent) | 270 | 70 | 226 (84) | 1 (Ref) | 20 (7) | 1 (Ref) | 22 (8) | 1 (Ref) | 199 (74) | 1 (Ref) | 46 (17) | 1 (Ref) |
| 7-valent vaccine | 988 | 64 | 806 (82) | 2.27 (1.76–2.92) | 64 (6) | 0.81 (0.53–1.23) | 100 (10) | 0.40 (0.29–0.54) | 651 (66) | 0.83 (0.65–1.04) | 106 (11) | 0.76 (0.55–1.06) |
| Non-13-valent vaccine | 484 | 65 | 304 (63) | 1 (Ref) | 38 (8) | 1 (Ref) | 101 (22) | 1 (Ref) | 339 (70) | 1 (Ref) | 66 (14) | 1 (Ref) |
| 1, 5, 7F (10-valent) | 354 | 53 | 316 (90) | 4.33 (2.92–6.40) | 13 (4) | 0.45 (0.23–0.85)# | 19 (5) | 0.20 (0.12–0.34) | 132 (37) | 0.25 (0.19–0.34) | 12 (3) | 0.22 (0.12–0.42) |
| Non 13-valent vaccine | 484 | 65 | 304 (63) | 1 (Ref) | 38 (8) | 1 (Ref) | 101 (22) | 1 (Ref) | 339 (70) | 1 (Ref) | 66 (14) | 1 (Ref) |
| 3, 6A, 19A (13-valent) | 270 | 70 | 226 (84) | 2.60 (1.79–3.79) | 20 (7) | 0.93 (0.53–1.64) | 22 (8) | 0.31 (0.19–0.51) | 199 (74) | 1.20 (0.86–1.67) | 46 (17) | 1.30 (0.86–1.96) |
| Non-13-valent vaccine | 484 | 65 | 304 (63) | 1 (Ref) | 38 (8) | 1 (Ref) | 101 (22) | 1 (Ref) | 339 (70) | 1 (Ref) | 66 (14) | 1 (Ref) |
| 13-valent vaccine | 1612 | 62 | 1348 (84) | 2.62 (2.07–3.31) | 97 (6) | 0.75 (0.51–1.11) | 141 (9) | 0.34 (0.26–0.45) | 982 (61) | 0.67 (0.54–0.83) | 164 (10) | 0.72 (0.53–0.97)# |
| Non-13-valent vaccine | 484 | 65 | 304 (63) | 1 (Ref) | 38 (8) | 1 (Ref) | 101 (22) | 1 (Ref) | 339 (70) | 1 (Ref) | 66 (14) | 1 (Ref) |
| Total | 2096 | 63 | 1652 (80) | 135 (6) | 242 (12) | 1321 (63) | 230 (11) | |||||
Bold indicates statistical significance. Ref: reference. #: not significant after adjustment for multiple comparisons (Holm’s method).